Research suggests gut-lung microbiome shifts may underlie clozapine's severe gastrointestinal and pulmonary adverse effects, offering potential mechanistic insights for managing this high-risk antipsychotic.
A single dose of psilocybin produced sustained depression symptom relief for months, highlighting its potential as a novel treatment for depression.
A completed study from San Francisco State University investigated using bilateral stimulation after meals to reduce anxiety in individuals recovering from eating disorders.
A multi-site clinical trial is evaluating tirzepatide for smoking cessation, representing a potential off-label or repurposing application of a GLP-1/GIP agonist in substance use disorder treatment.
An attorney is urging the DEA to expedite the rescheduling of psilocybin following a presidential order, highlighting regulatory shifts that may impact future clinical access to psychedelics.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from May 17 – May 22)
- Consider repurposing tocilizumab for treatment-resistant depression in patients with elevated inflammatory markers, pending further clinical efficacy data.
- Monitor for severe gastrointestinal and pulmonary adverse effects in patients on clozapine, as gut-lung microbiome shifts may be a contributing mechanism.
- Evaluate centanafadine as a novel non-stimulant option for adult ADHD, noting its promising profile in recent RCTs.
- Utilize baseline default mode network functional connectivity as a potential biomarker to predict escitalopram response in adolescents with major depressive disorder.
- Explore low-dose lithium as an off-label therapeutic strategy for managing behavioral symptoms in patients with mild cognitive impairment.
- Assess the potential of intranasal clozapine sol-gel formulations to reduce peripheral metabolic side effects while maintaining antipsychotic efficacy.
- Recognize that among currently studied psychedelics, only psilocybin has demonstrated robust efficacy for depression, distinguishing it from other agents in this class.
- Consider the potential off-label use of tirzepatide for smoking cessation, given ongoing multi-site clinical trial evaluations for this GLP-1/GIP agonist.
- Review expert guidelines on the recognition and treatment of bipolar disorder with mixed features to optimize management strategies for this complex presentation.
Mechanism of Action 2
Research indicates that a single dose of psilocybin may provide rapid relief from depression symptoms within days, highlighting its potential as a fast-acting therapeutic agent for major depressive disorder.
Preclinical data suggest KarXT (xanomeline-trospium) reverses cognitive deficits in a schizophrenia mouse model via gut microbiota modulation, offering potential insights into its mechanism and gastrointestinal side effects.
Diagnosis & Treatment 3
Study authors suggest optimal dosing for different ADHD medications
Low-dose lithium demonstrates potential therapeutic benefit for mild cognitive impairment, suggesting a possible off-label or repurposing opportunity for dementia-related behavioral symptoms.
A proof-of-concept RCT shows that a single dose of the anti-inflammatory agent tocilizumab cleared inflammation in depressed patients, though its clinical efficacy on depressive symptoms requires further investigation.
Drug Development 4
Research suggests repurposing a dementia drug targeting neuroinflammation as a potential treatment for alcohol withdrawal, offering a new pathway for alcohol use disorder management.
Compass Pathways plans to file for FDA approval of a psilocybin-based treatment for depression following successful Phase 3 trial results, representing a significant development in psychedelic psychiatry.
Preclinical rat data demonstrate that an intranasal clozapine sol-gel formulation achieves antipsychotic efficacy at 3.5% of the oral dose with reduced peripheral exposure and metabolic side effects, suggesting a promising delivery method for further clinical investigation.
This review of 53 RCTs identifies centanafadine as a promising novel non-stimulant treatment for adult ADHD, while noting that dasotraline showed promise in children before development was halted.
Podcast Summary 1
This podcast summary covers the recognition and treatment of bipolar disorder with mixed features, featuring expert commentary from Roger McIntyre, MD.
Clinical Pearl 1
A pilot randomized controlled trial published in JAMA Psychiatry suggests that an anti-inflammatory immunotherapy may be a promising treatment option for difficult-to-treat depression.